红细胞输注与急性肺栓塞患者结局
该回顾性研究纳入2000至2012年一家三级医院连续收治的以急性肺栓塞为主要诊断的患者,分析住院期间红细胞输注情况并经全州死亡数据库追踪死亡。住院期间5%的患者接受红细胞输注,输注组30天和6个月死亡率显著更高,多变量模型显示红细胞输注是30天和6个月死亡的独立预测因素。
要点
- 急性肺栓塞住院患者中红细胞输注少见,约为全部急性肺栓塞住院患者的5%。
- 接受红细胞输注者30天死亡率为19%对4%,6个月死亡率为40%对10%,均显著更高。
- 校正后红细胞输注仍与30天和6个月死亡风险升高独立相关,血红蛋白低于100 g/L亚组结果一致。
核心结论
- 急性肺栓塞住院患者中红细胞输注少见,且似与短期和长期死亡风险升高相关,该关联独立于入院时血红蛋白水平。
- 作者指出未来需开展随机对照研究评估红细胞输注对急性肺栓塞住院患者管理的影响。
研究设计与样本
- 回顾性研究,纳入2000至2012年一家三级医院连续收治的以急性肺栓塞为主要诊断的患者。
- 住院期间确定输血状态,死亡情况经全州死亡数据库追踪并用多变量模型分析。
- 共73例患者(占全部急性肺栓塞住院患者的5%)在住院期间接受红细胞输注。
主要发现
- 输注组患者年龄更大、合并症更多、血流动力学更差、简化肺栓塞严重指数评分更高,入院时血浆钠和血红蛋白水平更低。
- 未校正死亡率在输注组显著更高:30天为19%对4%(P < 0.001),6个月为40%对10%(P < 0.001)。
- 多变量模型显示红细胞输注是30天死亡的独立预测因素(比值比3.06,95%CI:1.17-8.01,P = 0.02)。
- 多变量模型显示红细胞输注是6个月死亡的独立预测因素(风险比1.97,95%CI:1.12-3.46,P = 0.02)。
- 敏感性分析证实,在血红蛋白<100 g/L的亚组中,输注患者死亡率高于未输注患者。
临床怎么用
- 对急性肺栓塞患者决定红细胞输注时应充分评估风险,输血可能提示预后不良而非仅由入院血红蛋白水平解释。
- 需结合患者年龄、合并症、血流动力学和严重指数评分综合判断,不宜仅依据血红蛋白水平决定输血。
局限性
- 为单中心回顾性研究,输血组仅73例,样本量有限。
- 输血与死亡风险的关联可能受未测量混杂因素影响,尚不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Blood transfusion has been associated with adverse outcomes in certain conditions. This study investigates the prevalence and outcomes of red blood cell (RBC) transfusion in patients with acute pulmonary embolism (PE). METHODS: Retrospective study of consecutive patients from 2000 to 2012 admitted to a tertiary hospital with a primary diagnosis of acute PE. Transfusion status during the hospital admission was ascertained. Mortality was tracked from a state-wide death database and analysed using multivariable modelling. RESULTS: A total of 73 patients (5% of all patients admitted with PE) received RBC transfusion during their admission. These patients were significantly older, had more co-morbidities, worse haemodynamics, higher simplified pulmonary embolism severity index scores, and lower plasma sodium and haemoglobin (Hb) levels at admission. Unadjusted mortality for the transfused group was significantly higher at 30-day (19% vs 4%, P < 0.001) and 6-month (40% vs 10%, P < 0.001) follow-up. Multivariable modelling showed RBC transfusion to be a significant independent predictor of mortality at 30-day (odds ratio 3.06, 95% CI: 1.17-8.01, P = 0.02) and 6-month (hazard ratio (HR) 1.97, 95% CI: 1.12-3.46, P = 0.02). Sensitivity analysis confirmed that transfused patients had higher mortality than non-transfused patients in the subgroup of patients with Hb <100 g/L. CONCLUSION: RBC transfusion in patients hospitalized with acute PE is rare and appears to be associated with increased risk of short- and long-term mortality, independent of Hb level on admission. This finding underscores the need for future randomized controlled studies on the impact of RBC transfusion in the management of patients admitted with acute PE. [Correction added on 4 May 2018, after first online publication: the word 'serum' was changed to 'plasma' throughout the article where appropriate.].
引用
- Wong CCY, Chow WWK, Lau JK, et al. Red blood cell transfusion and outcomes in acute pulmonary embolism. Respirology. 2018. PMID: 29693295. doi:10.1111/resp.13314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。